Genomics Company in Chicago - start up and/or large company - Avis employé Variant Scientist Tempus AI

2,0
17 août 2022
Recommande
Approbation du PDG
Perspective commerciale

Avantages

It's one of the only genomics companies in Chicago. The office was quite nice. Overall it's a fine place to work, especially if you want to stay in the area. There is unlimited PTO.

Inconvénients

The hours can be quite long and turnover is pretty high. Issues scaling to meet demand

Découvrez plus d’avis sur Tempus AI

5,0
27 mai 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Great for adding healthcare experience to your resume Start Up Perks Informal environment

Inconvénients

Lack of benefits Inexperienced colleagues and management

2,0
12 mars 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

As mentioned work is great since it is cancer research and my coworkers are amazing. Immediate leadership managers and Sr. managers are good as well but somewhat unorganised. Work life balance is good also and health insurance as long as you get BCBS PPO with copay otherwise you're screwed paying off deductible.

Inconvénients

Pay is below industry average, and there is essentially no room to negotiate a better raise. Employees are actively discouraged from discussing compensation, and whatever leadership decides is final, there are no exceptions. If you try to escalate concerns or request a conversation with senior leadership, such as a senior director or VP, you’ll quickly find yourself getting the runaround. Leadership prefers to hide behind layers of management rather than engage directly. There is also no clear or transparent path for career advancement. Opportunities technically exist, but they are extremely limited. You can do everything right, receive a top rating of 5 on your annual performance review, and still not be promoted to manager or see any meaningful improvement in compensation. To make matters worse, the billionaire CEO and founder has said things like, “Don’t worry about pay because we’re curing cancer.” Statements like that feel incredibly out of touch when employees are earning $50k–$60k a year and receiving annual raises of only about $2,000. On top of that, equity is almost impossible to obtain. You have to fight for even the possibility of it, because stock or equity compensation is reserved almost exclusively for the C-suite and directors, with virtually nothing available for employees below that level.

2
Voir les avis par: Utile|Évaluation|Date|Tout